R.R. Baliga/LinkedIn
Jul 1, 2026, 08:48
R.R. Baliga: The New JACC/ACC 2026 Statement Reinforces That DOAC Therapy Is Never One Size Fits All
R.R. Baliga, Editor-In-Chief of Textbook of Internal Medicine: Helping You Become a Great Doc, shared on LinkedIn:
”New JACC/ACC 2026 Scientific Statement spotlight: DOACs are now central to stroke and venous thromboembolism prevention—but not ‘one size fits all.’
The practical message: choose the right agent, dose correctly, avoid DOACs in mechanical valves and rheumatic mitral stenosis, reassess renal/liver function, bleeding risk, drug interactions, adherence, and cost.
In anticoagulation, the prescription is only the opening move; follow-up is where safety lives.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver